Intercept‐AD: Development and qualification of a highly sensitive immunoassay to detect total sabirnetug (ACU193) in human CSF
Hao Zhang, Sarah Monsheimer, Jennifer Gillies, Derrick Johnson, Nathan McOwen, Erika N Cline, Mahsan Rafizadeh, Robert A Dean, Jerome A Moore, Jasna Jerecic · 2025
Read Intercept‐AD: Development and qualification of a highly sensitive immunoassay to detect total sabirnetug (ACU193) in human CSF by Hao Zhang, Sarah Monsheimer, Jennifer Gillies, Derrick Johnson, Nathan McOwen, Erika N Cline, Mahsan Rafizadeh, Robert A Dean, Jerome A Moore, Jasna Jerecic (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713936.txt.
Description
Hao Zhang and co-authors develop a sensitive assay for an Alzheimer's drug in spinal fluid in a 2025 paper. The drug, sabirnetug, targets soluble amyloid oligomers early in disease. Measuring it in cerebrospinal fluid needs extreme sensitivity. A phase one trial supplied the samples.
The immunoassay runs on a commercial platform with signal boosting. Twenty-four antibody pairs were screened for the job. Two anti-drug antibodies were chosen for capture and detection. Selectivity, linearity, and stability were all qualified carefully. Spike tests checked interference from amyloid forms. Total drug, bound and unbound, is what the assay reports. Stability covered room temperature hours and freeze-thaw cycles. The quantitation floor reached very low levels. Trial pharmacokinetics rest on this measurement base. The authors detail parameters for replication by other labs.
Catalog record
| CREATOR | Hao Zhang, Sarah Monsheimer, Jennifer Gillies, Derrick Johnson, Nathan McOwen, Erika N Cline, Mahsan Rafizadeh, Robert A Dean, Jerome A Moore, Jasna Jerecic |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 3 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |